Tourmaline Bio, Inc. presented trial data at the ESC Congress 2025 in Madrid, Spain, led by the company's advisory board chair.
2 reports, 1 independent
Updated Aug 31
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tourmaline Bio, Inc. presented trial data at the ESC Congress 2025 in Madrid, Spain, led by the company's advisory board chair.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Society of Cardiology
non-profit knowledge-based professional association
-
Spain
country in southwestern Europe with territories in Africa
Related events
- Tenax Therapeutics presented findings and announced results at the European Society of Cardiology Congress 2026.
- The European Society of Cardiology Congress is currently being held in Munich, with trials targeting enrollment from both countries.
- BridgeBio presented data at the annual ESC Congress in 2026, with Marianna Fontana affiliated with UCL.
Coverage
Newest first; wire copies grouped- GlobeNewswireTourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress – Poster presentation highlights the consistency of reductions in high-sens
- GlobeNewswireTourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025,